CD274 and non-small cell lung carcinoma: Moreover, in NSCLC, ICIs targeting PD1/PD-L1 proved a significant OS benefit over the conventional chemotherapy, and, since 2015, nivolumab, pembrolizumab and atezolizumab were approved by FDA after the first-line treatment, independently by the hystologic type, while pembrolizumab received the approval as front-line therapy in patients with >50% PD-L1 expression [28].